Ruiz ÁJ, Vargas-Uricoechea H, Urina-Triana M, Román-González A, Isaza D, Etayo E, Quintero A, Molina DI, Toro JM, Parra G, Merchán A, Cadena A, Yupanqui Lozano H, Cárdenas JM, Quintero ÁM, Botero R, Jaramillo M, Arteaga JM, Vesga-Angarita B, Valenzuela-Plata E, Betancur-Valencia M. Dyslipidaemias and their treatment in high complexity centres in Colombia.
Clin Investig Arterioscler 2020;
32:101-110. [PMID:
32284160 DOI:
10.1016/j.arteri.2019.11.005]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 11/05/2019] [Accepted: 11/19/2019] [Indexed: 06/11/2023]
Abstract
BACKGROUND AND OBJECTIVE
Data is scarce on the distribution of different types of dyslipidaemia in Colombia. The primary objective was to describe the frequency of dyslipidaemias. The secondary objectives were: frequency of cardiovascular comorbidity, statins and other lipid-lowering drugs use, frequency of statins intolerance, percentage of patients achieving c-LDL goals, and distribution of cardiovascular risk (CVR).
MATERIALS AND METHODS
Cross-sectional study with retrospective data collection from 461 patients diagnosed with dyslipidaemia and treated in 17 highly specialised centres distributed into six geographic and economic regions of Colombia.
RESULTS
Mean (SD) age was 66.4 (±12.3) years and 53.4% (246) were women. Dyslipidaemias were distributed as follows in order of frequency: mixed dyslipidaemia (51.4%), hypercholesterolaemia (41.0%), hypertriglyceridaemia (5.4%), familial hypercholesterolaemia (3.3%), and low c-HDL (0.7%). The most prescribed drugs were atorvastatin (75.7%) followed by rosuvastatin (24.9%). As for lipid control, 55% of all patients, and 28.6% of those with coronary heart disease, did not achieve their personal c-LDL goal despite treatment. The frequency of statin intolerance was 2.6% in this study.
CONCLUSIONS
Mixed dyslipidaemia and hypercholesterolaemia are the most frequent dyslipidaemias in Colombia. A notable percentage of patients under treatment with lipid-lowering drugs, including those with coronary heart disease, did not achieve specific c-LDL goals. This poor lipid control may worsen patient's CVR, so that therapeutic strategies need to be changed, either with statin intensification or addition of new drugs in patients with higher CVR.
Collapse